Alpine Associates Management’s Inhibrx INBX Stock Holding History

Alpine Associates Management’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-305,967	Closed	-$4.34M	–	50
2024 Q2	$4.34M	Buy	+305,967	New	+$4.78M	0.21%	41

Other funds holding INBX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Slotnik Capital Dallas, Texas $342M AUM 105.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpine Associates Management's INBX Position: Q3 2024 in Review

Alpine Associates Management sold out of Inhibrx (INBX) in Q3 2024, closing a stake of 305,967 shares — an estimated $4.34M sold.

Alpine Associates Management first reported a position in INBX in Q2 2024 and held it in 1 quarter. The position peaked at $4.34M in Q2 2024. 96 funds tracked by Wall St. Rank hold INBX as of Q3 2024.

Alpine Associates Management reported no remaining Inhibrx position as of Q3 2024 after selling out during the quarter.
Alpine Associates Management sold 305,967 Inhibrx shares in Q3 2024, an estimated $4.34M.
Alpine Associates Management first reported a position in Inhibrx in Q2 2024 and held it in 1 quarter.
Alpine Associates Management's Inhibrx position peaked at $4.34M in Q2 2024.
96 funds tracked by Wall St. Rank held Inhibrx as of Q3 2024.

Based on Alpine Associates Management's 13F filing for Q3 2024, filed 8 Nov 2024.